Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.73
PCRX's Cash to Debt is ranked higher than
57% of the 750 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. PCRX: 0.73 )
PCRX' s 10-Year Cash to Debt Range
Min: 0.73   Max: No Debt
Current: 0.73

Equity to Asset 0.24
PCRX's Equity to Asset is ranked lower than
56% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.60 vs. PCRX: 0.24 )
PCRX' s 10-Year Equity to Asset Range
Min: -0.73   Max: 0.59
Current: 0.24

-0.73
0.59
F-Score: 4
Z-Score: 6.95
M-Score: -1.98
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -62.29
PCRX's Operating margin (%) is ranked lower than
53% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.34 vs. PCRX: -62.29 )
PCRX' s 10-Year Operating margin (%) Range
Min: -325.77   Max: -62.29
Current: -62.29

-325.77
-62.29
Net-margin (%) -74.70
PCRX's Net-margin (%) is ranked lower than
54% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. PCRX: -74.70 )
PCRX' s 10-Year Net-margin (%) Range
Min: -300.62   Max: -74.7
Current: -74.7

-300.62
-74.7
ROE (%) -154.93
PCRX's ROE (%) is ranked lower than
59% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. PCRX: -154.93 )
PCRX' s 10-Year ROE (%) Range
Min: -558.91   Max: -79.39
Current: -154.93

-558.91
-79.39
ROA (%) -37.63
PCRX's ROA (%) is ranked lower than
54% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.95 vs. PCRX: -37.63 )
PCRX' s 10-Year ROA (%) Range
Min: -82.83   Max: -37.63
Current: -37.63

-82.83
-37.63
ROC (Joel Greenblatt) (%) -89.11
PCRX's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.63 vs. PCRX: -89.11 )
PCRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -251.5   Max: -89.11
Current: -89.11

-251.5
-89.11
Revenue Growth (%) -53.30
PCRX's Revenue Growth (%) is ranked lower than
58% of the 549 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. PCRX: -53.30 )
PCRX' s 10-Year Revenue Growth (%) Range
Min: -67   Max: -53.3
Current: -53.3

-67
-53.3
EBITDA Growth (%) -64.00
PCRX's EBITDA Growth (%) is ranked lower than
58% of the 504 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.00 vs. PCRX: -64.00 )
PCRX' s 10-Year EBITDA Growth (%) Range
Min: -70.2   Max: -64
Current: -64

-70.2
-64
EPS Growth (%) -65.60
PCRX's EPS Growth (%) is ranked lower than
57% of the 506 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. PCRX: -65.60 )
PCRX' s 10-Year EPS Growth (%) Range
Min: -68.6   Max: -65.6
Current: -65.6

-68.6
-65.6
» PCRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

PCRX Guru Trades in Q1 2013

RS Investment Management 518,567 sh (New)
Steven Cohen 110,088 sh (-21.37%)
» More
Q2 2013

PCRX Guru Trades in Q2 2013

Mariko Gordon 10,982 sh (New)
Steven Cohen 110,700 sh (+0.56%)
RS Investment Management 491,216 sh (-5.27%)
» More
Q3 2013

PCRX Guru Trades in Q3 2013

Mariko Gordon 429,688 sh (+3812.66%)
RS Investment Management 438,716 sh (-10.69%)
Steven Cohen 85,300 sh (-22.94%)
» More
Q4 2013

PCRX Guru Trades in Q4 2013

Jim Simons 71,500 sh (New)
Ron Baron 6,495 sh (New)
Mariko Gordon 1,304,190 sh (+203.52%)
Steven Cohen 103,600 sh (+21.45%)
RS Investment Management 328,916 sh (-25.03%)
» More
» Details

Insider Trades

Latest Guru Trades with PCRX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mariko Gordon 2013-12-31 Add 203.52%2.08%$47.74 - $56.97 $ 66.0526%1304190
Ron Baron 2013-12-31 New Buy$47.74 - $56.97 $ 66.0526%6495
Mariko Gordon 2013-09-30 Add 3812.66%0.93%$30.01 - $47.47 $ 66.0582%429688
Mariko Gordon 2013-06-30 New Buy0.02%$25.84 - $30.26 $ 66.05128%10982
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Pacira Pharmaceuticals, Inc.

Baron Funds Comments on Pacira Pharmaceuticals - Mar 05, 2014

Pacira Pharmaceuticals, Inc. (PCRX) is a vertically integrated (IP to manufacturing) pharmaceutical company. Its main line of business is the sale of a drug called EXPAREL, which was approved by the FDA in October 2011 and launched in the U.S. in April 2012. EXPAREL is a pain control drug (using slow release bupivacaine) injected directly into the wound/cut site during a surgical procedure, prior to closing the incision. It is also being studied for use as a nerve block agent for additional procedures. Bupivacaine is a well-known drug that has been used for decades during surgery. Its safety profile is well understood. The key advantage of EXPAREL over generic bupivacaine is that it incorporates a proprietary time-release "wrapper" called DepoFoam that lets the pain relief delivered by bupivacaine last for up to three days post-surgery. This enables reduced usage of dangerous opiates and other treatments, such as pain balls. In the end, we believe that based on clinical studies, EXPAREL is cheaper, safer and more effective than current pain management practices. We believe that EXPAREL has significant IP protection and has limited potential competitors.

Uptake among large hospital formularies has been brisk, and EXPAREL has been at least initially purchased at over 75% of the top 100 hospitals in the U.S. and most of the top 500 hospitals.Yet penetration of the potential $40 million procedure market is still minimal. Most current sales are for soft tissue procedures, but orthopedic studies also look promising. EXPAREL did about $14.5 million in sales in 2012, which grew to about $76 million in 2013 based on information recently released by the company. The fourth quarter annualized run rate of the drug is over $120 million.This means that the company is going to have to expand capacity from its current $100 million volume plant. It has built capacity for up to $400 million in sales, and is awaiting what we believe will be near term approval from the FDA on the plant. We believe EXPAREL represents a worldwide market opportunity of potentially billions of dollars and that it is just at the start of its overall volume penetration.Additionally, the company has longer term plans to use its DepoFoam "wrapper" technology on other drugs, including methotrexate (for rheumatoid arthritis). If this massive opportunity set is properly exploited, we believe that Pacira could become a billion dollar revenue company within a few years, and earnings per share could ultimately exceed $10 on EXPAREL alone. At a current price of $65, shares trade at only 6.5x this level, and it's possible that they could trade at 15-20x if growth hits our expectations.

From Ron Baron (Trades, Portfolio)'s Baron Funds fourth quarter 2013 commentary.

Check out Ron Baron latest stock trades

Top Ranked Articles about Pacira Pharmaceuticals, Inc.

Baron Funds Comments on Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc. (PCRX) is a vertically integrated (IP to manufacturing) pharmaceutical company. Its main line of business is the sale of a drug called EXPAREL, which was approved by the FDA in October 2011 and launched in the U.S. in April 2012. EXPAREL is a pain control drug (using slow release bupivacaine) injected directly into the wound/cut site during a surgical procedure, prior to closing the incision. It is also being studied for use as a nerve block agent for additional procedures. Bupivacaine is a well-known drug that has been used for decades during surgery. Its safety profile is well understood. The key advantage of EXPAREL over generic bupivacaine is that it incorporates a proprietary time-release "wrapper" called DepoFoam that lets the pain relief delivered by bupivacaine last for up to three days post-surgery. This enables reduced usage of dangerous opiates and other treatments, such as pain balls. In the end, we believe that based on clinical studies, EXPAREL is cheaper, safer and more effective than current pain management practices. We believe that EXPAREL has significant IP protection and has limited potential competitors. Read more...

Ratios

vs
industry
vs
history
P/B 55.00
PCRX's P/B is ranked lower than
77% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.84 vs. PCRX: 55.00 )
PCRX' s 10-Year P/B Range
Min: 3.47   Max: 63.46
Current: 55

3.47
63.46
P/S 26.30
PCRX's P/S is ranked lower than
84% of the 717 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.95 vs. PCRX: 26.30 )
PCRX' s 10-Year P/S Range
Min: 0.39   Max: 30.37
Current: 26.3

0.39
30.37
EV-to-EBIT 9.90
PCRX's EV-to-EBIT is ranked higher than
89% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.45 vs. PCRX: 9.90 )
PCRX' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 9.9

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 77.00
PCRX's Price/Tangible Book is ranked lower than
90% of the 639 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.10 vs. PCRX: 77.00 )
PCRX' s 10-Year Price/Tangible Book Range
Min: 5.09   Max: 65.33
Current: 77

5.09
65.33
Price/Median PS Value 1.90
PCRX's Price/Median PS Value is ranked lower than
66% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.10 vs. PCRX: 1.90 )
PCRX' s 10-Year Price/Median PS Value Range
Min: 0.62   Max: 1.64
Current: 1.9

0.62
1.64

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:82P.Germany
Pacira Pharmaceuticals, Inc., was incorporated in December 2006 and has only been conducting operations with respect to EXPAREL since March 2007. The company is a pharmaceutical company engaged in the development, commercialization and manufacture of proprietary pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. On October 28, 2011, the United States Food and Drug Administration, or FDA, approved its New Drug Application, or NDA, for its lead product candidate, EXPAREL, a liposome injection of bupivacaine, an amide local anesthetic, indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. Its clinical data demonstrates that EXPAREL provides analgesia for up to 72 hours post-surgery, compared with approximately eight hours or less for bupivacaine. Bupivacaine and other shorter acting local anesthetics of the amide type such as mepivacaine and lidocaine are commonly used as the first line of treatment, pre- and post-operatively, of a multimodal postsurgical pain treatment regimen. EXPAREL is being launched by certain members of its management team who have successfully launched multiple products in the hospital market. Its commercial team has executed on a full range of pre-launch activities for EXPAREL including: (i) publications and abstracts for the EXPAREL clinical program efficacy and safety, health outcomes studies, and review articles on postsurgical pain management; (ii) health outcomes studies which provide retrospective and prospective analyses for its hospital customers using their own hospital data to demonstrate the true cost of opioid-based postsurgical pain management; (iii) key opinion leader, or KOL, development programs and advisory boards to address topics of best practice techniques, guidelines and protocols for the use of EXPAREL, educational needs of its physician, pharmacist and registered nurse customers, nerve block clinical studies and additional indications for the future development of EXPAREL and (iv) education initiatives such as center of excellence programs, preceptorship programs, pain protocols and predictive models for enhanced patient care, web-based training and virtual launch programs. Its current product development activities utilize its proprietary DepoFoam drug delivery technology. DepoFoam consists of microscopic spherical particles composed of a honeycomb-like structure of numerous internal aqueous chambers containing an active drug ingredient. Its other products include: Depocyt(e) - It is a sustained-release liposomal formulation of the chemotherapeutic agent cytarabine utilizing its DepoFoam technology. Depocyt(e) is indicated for the intrathecal treatment of lymphomatous meningitis, a life-threatening complication of lymphoma, a cancer of the immune system. Lymphomatous meningitis can be controlled with conventional cytarabine, but because of the drug's short

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide